Institution
University of Turin
Education•Turin, Piemonte, Italy•
About: University of Turin is a education organization based out in Turin, Piemonte, Italy. It is known for research contribution in the topics: Population & Cancer. The organization has 29607 authors who have published 77952 publications receiving 2480900 citations. The organization is also known as: Universita degli Studi di Torino & Università degli Studi di Torino.
Topics: Population, Cancer, Medicine, Transplantation, Context (language use)
Papers published on a yearly basis
Papers
More filters
••
01 Jun 1986TL;DR: In this paper, a class of Petri nets in which transitions can fire after either a deterministic or a random, exponentially distributed, firing delay is defined, and a solution technique is presented to obtain the steady-state probability distribution over markings, introducing restrictions on the use of deterministic firing delays.
Abstract: A class of Petri nets (DSPN) in which transitions can fire after either a deterministic or a random, exponentially distributed, firing delay is defined, and a solution technique is presented to obtain the steady-state probability distribution over markings, introducing restrictions on the use of deterministic firing delays. An example of application of this modeling technique is presented to demonstrate the impact that the use of a mix of deterministic and exponentially distributed firing delays (instead of all exponentially distributed firing delays) can have on performance and reliability estimates.
377 citations
••
01 May 2010
TL;DR: The prognosis for patients with idiopathic pulmonary fibrosis may be accurately determined using four readily ascertainable predictors, and a simplified scoring system may be a valuable tool for determining prognosis and guiding clinical management.
Abstract: Rationale: Several predictors of mortality in patients with idiopathic pulmonary fibrosis have been described; however, there is a need for a practical and accurate method of quantifying the prognosis of individual patients.Objectives: Develop a practical mortality risk scoring system for patients with idiopathic pulmonary fibrosis.Methods: We used a Cox proportional hazards model and data from two clinical trials (n = 1,099) to identify independent predictors of 1-year mortality among patients with idiopathic pulmonary fibrosis. From the comprehensive model, an abbreviated clinical model comprised of only those predictors that are readily and reliably ascertained by clinicians was derived. Beta coefficients for each predictor were then used to develop a practical mortality risk scoring system.Measurements and Main Results: Independent predictors of mortality included age, respiratory hospitalization, percent predicted FVC, 24-week change in FVC, percent predicted carbon monoxide diffusing capacity, 24-we...
376 citations
••
French Institute of Health and Medical Research1, Katholieke Universiteit Leuven2, Ben-Gurion University of the Negev3, German Cancer Research Center4, Istituto Superiore di Sanità5, University of Turin6, Georgia Regents University7, University of Oxford8, Cardiff University9, Oregon Health & Science University10, Yale University11, Cold Spring Harbor Laboratory12, University of Pennsylvania13, University of Burgundy14, National Institutes of Health15, Georgetown University16, University of Miami17, Icahn School of Medicine at Mount Sinai18, GlaxoSmithKline19, University of Paris20, Centre national de la recherche scientifique21, Heidelberg University22, University of Pittsburgh23, Karolinska Institutet24, Hamad Medical Corporation25, University of Sheffield26, Centre Hospitalier Universitaire de Toulouse27, University of Lausanne28, University of Milan29, University of Navarra30, Leiden University31, University of Texas Health Science Center at Houston32, Istituto Giannina Gaslini33, Roswell Park Cancer Institute34, University of California, San Francisco35, Northwestern University36, Johns Hopkins University37, Main Line Health38, Thomas Jefferson University39, University of Buenos Aires40, Memorial Sloan Kettering Cancer Center41, University of Chicago42, Martin Luther University of Halle-Wittenberg43, Mie University44, University of Lisbon45, University of Queensland46, QIMR Berghofer Medical Research Institute47, Ludwig Institute for Cancer Research48, University of Connecticut49, University of Nebraska Medical Center50, Université catholique de Louvain51, Mayo Clinic52, Technische Universität München53, University of South Florida54, Cornell University55, University of Michigan56
TL;DR: A critical, integrated classification of anticancer immunotherapies is proposed and the clinical relevance of these approaches is discussed.
Abstract: During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical studies. Immunotherapies may be subdivided into "passive" and "active" based on their ability to engage the host immune system against cancer. Since the anticancer activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies on the host immune system, this classification does not properly reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer immunotherapeutics can be classified according to their antigen specificity. While some immunotherapies specifically target one (or a few) defined tumor-associated antigen(s), others operate in a relatively non-specific manner and boost natural or therapy-elicited anticancer immune responses of unknown and often broad specificity. Here, we propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches.
375 citations
••
Katholieke Universiteit Leuven1, Imperial College London2, VU University Amsterdam3, University of Antwerp4, University of Zurich5, University of Lausanne6, Autonomous University of Barcelona7, University of Aberdeen8, Institut Gustave Roussy9, University of Duisburg-Essen10, University of New Mexico11, The Chinese University of Hong Kong12, Trinity College, Dublin13, University of Turin14, University of Chieti-Pescara15, Aarhus University16, Roswell Park Cancer Institute17, Aberdeen Royal Infirmary18, University of Franche-Comté19
TL;DR: A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early-stage disease and locally advanced disease.
375 citations
••
University of Hamburg1, Thomas Jefferson University2, University of Texas MD Anderson Cancer Center3, University of Antwerp4, University of Bern5, Humboldt University of Berlin6, King's College London7, Université libre de Bruxelles8, Université catholique de Louvain9, Maastricht University10, University of Texas Southwestern Medical Center11, University of Turin12, Hannover Medical School13, Katholieke Universiteit Leuven14, University of Groningen15, Medical University of Graz16, University of Liverpool17, Boston University18, University of Reading19, Medical University of Vienna20, University of Upper Alsace21
TL;DR: The screening of patients, optimization of therapeutic schemes, monitoring of cardiovascular function during treatment, and the management of cardiovascular side effects are likely to become increasingly important in cancer patients.
Abstract: The reductions in mortality and morbidity being achieved among cancer patients with current therapies represent a major achievement. However, given their mechanisms of action, many anti-cancer agents may have significant potential for cardiovascular side effects, including the induction of heart failure. The magnitude of this problem remains unclear and is not readily apparent from current clinical trials of emerging targeted agents, which generally under-represent older patients and those with significant co-morbidities. The risk of adverse events may also increase when novel agents, which frequently modulate survival pathways, are used in combination with each other or with other conventional cytotoxic chemotherapeutics. The extent to which survival and growth pathways in the tumour cell (which we seek to inhibit) coincide with those in cardiovascular cells (which we seek to preserve) is an open question but one that will become ever more important with the development of new cancer therapies that target intracellular signalling pathways. It remains unclear whether potential cardiovascular problems can be predicted from analyses of such basic signalling mechanisms and what pre-clinical evaluation should be undertaken. The screening of patients, optimization of therapeutic schemes, monitoring of cardiovascular function during treatment, and the management of cardiovascular side effects are likely to become increasingly important in cancer patients. This paper summarizes the deliberations of a cross-disciplinary workshop organized by the Heart Failure Association of the European Society of Cardiology (held in Brussels in May 2009), which brought together clinicians working in cardiology and oncology and those involved in basic, translational, and pharmaceutical science.
375 citations
Authors
Showing all 30045 results
Name | H-index | Papers | Citations |
---|---|---|---|
Michael Grätzel | 248 | 1423 | 303599 |
Lewis C. Cantley | 196 | 748 | 169037 |
Kenneth C. Anderson | 178 | 1138 | 126072 |
Elio Riboli | 158 | 1136 | 110499 |
Giacomo Bruno | 158 | 1687 | 124368 |
Silvia Franceschi | 155 | 1340 | 112504 |
Thomas E. Starzl | 150 | 1625 | 91704 |
Paolo Boffetta | 148 | 1455 | 93876 |
Marco Costa | 146 | 1458 | 105096 |
Pier Paolo Pandolfi | 146 | 529 | 88334 |
Andrew Ivanov | 142 | 1812 | 97390 |
Chiara Mariotti | 141 | 1426 | 98157 |
Tomas Ganz | 141 | 480 | 73316 |
Jean-Pierre Changeux | 138 | 672 | 76462 |
Dong-Chul Son | 138 | 1370 | 98686 |